Next Article in Journal / Special Issue
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
Previous Article in Journal
Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer
Previous Article in Special Issue
Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
Open AccessReview

Targeting Autophagy in ALK-Associated Cancers

by Julie Frentzel 1,†, Domenico Sorrentino 2,† and Sylvie Giuriato 2,3,4,*
1
Merck Serono S.A., Route de Fenil 25, Z.I. B, 1804 Corsier-sur-Vevey, Switzerland
2
Inserm, UMR1037, CNRS, ERL5294, Université Toulouse III-Paul Sabatier, CRCT, F-31000 Toulouse, France
3
European Research Initiative on ALK-related malignancies (ERIA)
4
TRANSAUTOPHAGY: European Network for Multidisciplinary Research and Translation of Autophagy Knowledge, COST Action CA15138
*
Author to whom correspondence should be addressed.
These authors have contributed equally to this work.
Cancers 2017, 9(12), 161; https://doi.org/10.3390/cancers9120161
Received: 31 October 2017 / Revised: 17 November 2017 / Accepted: 23 November 2017 / Published: 27 November 2017
(This article belongs to the Special Issue Targeting ALK in Cancer)
Autophagy is an evolutionarily conserved catabolic process, which is used by the cells for cytoplasmic quality control. This process is induced following different kinds of stresses e.g., metabolic, environmental, or therapeutic, and acts, in this framework, as a cell survival mechanism. However, under certain circumstances, autophagy has been associated with cell death. This duality has been extensively reported in solid and hematological cancers, and has been observed during both tumor development and cancer therapy. As autophagy plays a critical role at the crossroads between cell survival and cell death, its involvement and therapeutic modulation (either activation or inhibition) are currently intensively studied in cancer biology, to improve treatments and patient outcomes. Over the last few years, studies have demonstrated the occurrence of autophagy in different Anaplastic Lymphoma Kinase (ALK)-associated cancers, notably ALK-positive anaplastic large cell lymphoma (ALCL), non-small cell lung carcinoma (NSCLC), Neuroblastoma (NB), and Rhabdomyosarcoma (RMS). In this review, we will first briefly describe the autophagic process and how it can lead to opposite outcomes in anti-cancer therapies, and we will then focus on what is currently known regarding autophagy in ALK-associated cancers. View Full-Text
Keywords: ALK (anaplastic lymphoma kinase) oncogene; anaplastic large cell lymphoma (ALCL); non-small cell lung carcinoma (NSCLC); neuroblastoma (NB); rhabdomyosarcoma (RMS); tyrosine kinase inhibitor (TKI); combined therapy; cytoprotective autophagy; cytotoxic autophagy; autophagic switch ALK (anaplastic lymphoma kinase) oncogene; anaplastic large cell lymphoma (ALCL); non-small cell lung carcinoma (NSCLC); neuroblastoma (NB); rhabdomyosarcoma (RMS); tyrosine kinase inhibitor (TKI); combined therapy; cytoprotective autophagy; cytotoxic autophagy; autophagic switch
Show Figures

Figure 1

MDPI and ACS Style

Frentzel, J.; Sorrentino, D.; Giuriato, S. Targeting Autophagy in ALK-Associated Cancers. Cancers 2017, 9, 161.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop